Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Clinical Trials Search Results
Search History:
Count: 81
Selected: 0
| NCT ID | Title | ||
|---|---|---|---|
| NCT02631642 | A Study of HMPL-689 in Healthy Volunteers | ||
| NCT04923945 | Savolitinib for Treating Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Patients | ||
| NCT02589821 | Phase III Study of Surufatinib in Treating Advanced Pancreatic Neuroendocrine Tumors | ||
| NCT04923932 | Savolitinib for Treating Gastric Cancer and Esophagogastric Junction Adenocarcinoma Patients | ||
| NCT04272957 | A Study of HMPL-306 in Patients With IDH1 and/or IDH2 Mutation of Relapsed/Refractory Myeloid Leukemia/Neoplasms | ||
| NCT04290325 | HMPL-453 in Advanced Malignant Mesothelioma | ||
| NCT04755075 | Surufatinib Hepatic Impairment Study | ||
| NCT04372394 | A Study to Assess the Effect of a High Fat Meal on Surufatinib in Healthy Subjects | ||
| NCT03778229 | Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib | ||
| NCT02601274 | Study of Theliatinib (HMPL-309) in Patients With Advanced Solid Tumor | ||
| NCT01645215 | Phase I Study of Fruquintinib(HMPL-013) in Patients With Advanced Solid Tumors | ||
| NCT05522738 | Safety and Efficacy of Fruquintinib+FOLFIRI in RAS-mutated Metastatic Colorectal Cancer | ||
| NCT05842525 | Fruquintinib Plus FOLFIRI in RAS-mutated Metastatic Colorectal Cancer | ||
| NCT03684967 | Study of Fruquintinib (HMPL-013) in High Risk Patients With Advanced NSCLC | ||
| NCT03860532 | Phase I Clinical Trial in Healthy Male Volunteers | ||
| NCT02133157 | Phase I Study of Sulfatinib(HMPL-012) in Patients With Advanced Solid Tumors | ||
| NCT05173142 | HMPL-453 (FGFR Inhibitor) in Combination With Chemotherapy or Anti-PD-1 Antibody in Advanced Solid Tumors | ||
| NCT02503033 | A Study of HMPL-523 in Relapsed or Refractory Hematologic Malignancies | ||
| NCT03860948 | A Pharmacokinetic and Bioequivalence Study of Savolitinib Tablets in Healthy Chinese Male Volunteers | ||
| NCT05029635 | Phase III Study on HMPL-523 for Treatment of ITP | ||
| NCT02252913 | A Study of Safety and Pharmacokinetics of Volitinib With Docetaxel in Patients With Advanced Gastric Cancer | ||
| NCT05318820 | A Clinical Study to Evaluate the Pharmacokinetics and Bioequivalence of HMPL-523 Tablets Produced by Two Different Manufacturers | ||
| NCT03976856 | Safety and Efficacy of Genolimzumab (GB226) in Combination With Fruquintinib | ||
| NCT03223376 | A Phase III Study of Fruquintinib in Combination With Paclitaxel in Second Line Gastric Cancer(FRUTIGA) | ||
| NCT02966821 | Study of Surufatinib as Second-line Treatment in Patients With Biliary Tract Carcinoma | ||
| NCT02590952 | A Phase I Study of Epitinib(HMPL-813) in Patients With Advanced Solid Tumors | ||
| NCT02966171 | A Dose Escalation Study to Assess the Safety and Tolerability of HMPL-453 in Patients With Advanced Solid Malignancies | ||
| NCT03597971 | HMPL004-6599 Phase I Dose-escalating Study | ||
| NCT02588170 | Phase III Study of Surufatinib in Treating Advanced Extrapancreatic Neuroendocrine Tumors | ||
| NCT02415023 | A Phase Ib/2 Clinical Study of Fruquintinib Combined With Paclitaxel in the Treatment of Advanced Gastric Cancer | ||
| NCT05509699 | Surufatinib Plus Anti-PD-1/L1 as Maintenance Therapy in Extensive-Stage Small Cell Lung Cancer | ||
| NCT03251378 | A Multi-Center, Open-Label Study of Fruquintinib in Solid Tumors and Colorectal, and Breast Cancers | ||
| NCT01773018 | Phase I Study of the Volitinib (HMPL-504) in Patients With Advanced Solid Tumors | ||
| NCT01975077 | A Phase Ib Study of Fruquintinib in 3rd Line mCRC | ||
| NCT02267967 | Phase Ib/II Study of Sulfatinib in Treating Advanced Neuroendocrine Tumors | ||
| NCT00659802 | Phase II Study of HMPL-004 in Patients With Ulcerative Colitis | ||
| NCT03091192 | Savolitinib vs. Sunitinib in MET-driven PRCC. | ||
| NCT01955304 | Food Effect Study of Single Dose of Fruquintinib (HMPL-013) in Healthy Subjects | ||
| NCT03977090 | Geptanolimab(GB226) Combined With Fruquintinib in the Treatment of Metastatic Colorectal Cancer | ||
| NCT04510649 | Surufatinib DDI With a PPI and a CYP3A Inducer | ||
| NCT02196688 | Study of Fruquintinib in Patients With Metastatic Colorectal Cancer | ||
| NCT02320409 | A Food Effect Phase I Study of the Sulfatinib in Healthy Subjects (HMPL-012) | ||
| NCT02689752 | A Mass Balance Study to Investigate the Absorption, Metabolism, and Excretion Of [14C] Fruquintinib | ||
| NCT05535933 | HMPL-523 (Sovleplenib) in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia | ||
| NCT00655733 | Phase II Study of HMPL-004 in Subjects With Crohn's Disease | ||
| NCT02601248 | Study of Theliatinib (HMPL-309) in Patients With Advanced Solid Tumor | ||
| NCT04322539 | A Study of Efficacy and Safety of Fruquintinib (HMPL-013) in Participants With Metastatic Colorectal Cancer | ||
| NCT04169672 | Study of Surufatinib Single Agent or Surufatinib Combined With Toripalimab in Patients With Advanced Solid Tumors | ||
| NCT03128164 | A Study of HMPL-689 in Patients With Lymphomas Failed of Standard of Care or no Standard of Care Existed | ||
| NCT05015608 | Study on Savolitinib Combined With Osimertinib in Treatment of Advanced NSCLC With MET Amplification |
